Companies: 48,874 Total Market Cap: 132460447025120.92

Zai Lab Limited

NASDAQ: ZLAB
Healthcare Biotechnology
Rank #4078
Market Cap 3.58 B
Volume 887,450
Price 32.99
Change (%) 6.66%
Country or region China China

Zai Lab Limited's latest marketcap:

3.58 B

As of 05/19/2025, Zai Lab Limited's market capitalization has reached $3.58 B. According to our data, Zai Lab Limited is the 4078th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 3.58 B
Revenue (ttm) 418.33 M
Net Income (ttm) -252,070,000
Shares Out 108.47 M
EPS (ttm) -2.48
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 05/08/2025
Market Cap Chart
Data Updated: 05/19/2025

Zai Lab Limited's yearly market capitalization.

Zai Lab Limited has seen its market value drop from $11.91 B to $3.58 B since 2020, representing a total decrease of 69.96% and an annual compound decline rate (CAGR) of 24.00%.
Date Market Cap Change (%)
05/19/2025 $3.58 B 12.57%
12/31/2024 $2.85 B 6.15%
12/29/2023 $2.69 B -8.77%
12/30/2022 $2.95 B -51.37%
12/31/2021 $6.06 B -49.14%
12/31/2020 $11.91 B

Company Profile

About Zai Lab Limited

Zai Lab Limited is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for medical conditions in oncology, immunology, neuroscience, and infectious diseases.

Commercial Products

  • Zejula: An oral PARP inhibitor for ovarian cancer.
  • VYVGART: A human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
  • NUZYRA: Treats community-acquired bacterial pneumonia and acute bacterial skin infections.
  • Optune: A therapy for glioblastoma multiforme.
  • Qinlock: Targets gastrointestinal stromal tumors.
  • Xacduro: Addresses hospital-acquired and ventilator-associated bacterial pneumonia.
  • Augtyro: Treats ROS1-positive non-small cell lung cancer.

Pipeline Highlights

  • Oncology: Bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib.
  • Immunology & Neuroscience: Efgartigimod, xanomeline, and trospium chloride.

Strategic Collaborations

Zai Lab has key partnerships with leading biopharmaceutical companies, including:

  • Tesaro, Inc. (niraparib)
  • NovoCure Ltd. (Tumor Treating Fields)
  • Deciphera Pharmaceuticals (ripretinib)
  • Paratek Bermuda Ltd. (omadacycline)
  • argenx BV (efgartigimod)
  • Bristol-Myers Squibb (tisotumab vedotin & repotrectinib)
  • Amgen Inc. (bemarituzumab)
  • Innoviva, Inc. (Sulbactam-Durlobactam)
  • Karuna Therapeutics (Xanomeline & trospium chloride)
  • Pfizer Inc. (sulbactam & durlobactam)

Founded: 2013 | Headquarters: Shanghai, China

Frequently Asked Questions

As of 05/19/2025, Zai Lab Limited (including the parent company, if applicable) has an estimated market capitalization of $3.58 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Zai Lab Limited global market capitalization ranking is approximately 4078 as of 05/19/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region China
Founded 2013
IPO Date 09/20/2017
Employees 1,869
CEO Ying Du
Sector Healthcare
Industry Biotechnology
Address Jinchuang Plaza, Building 1, 4th Floor
Shanghai, 201210
China
Website https://www.zailaboratory.com
People Also Watch
VRTX
440.66 6.66%
CSL Limited
156.11 6.66%
REGN
596.54 6.66%
KRX-207940
735.02 6.66%